Latest News

Low-Dose Triple Pill vs Monotherapy for Hypertension
Written by: Cardiac Failure Review
Low-Dose Triple Pill vs Monotherapy for Hypertension
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Written by: Radcliffe Cardiology
Acoramidis Reduces Cumulative CV Events in ATTR-CM
Beta-Blockers Post-MI Show No Benefit in Preserved LVEF
Written by: Radcliffe Cardiology
Beta-Blockers Post-MI Show No Benefit in Preserved LVEF
Delayed ATTR-CM Diagnosis Common in HF Patients
Written by: Radcliffe Cardiology
Delayed ATTR-CM Diagnosis Common in HF Patients
TTR Therapies Show Delayed Mortality Benefit in ATTR-CM
Written by: Radcliffe Cardiology
TTR Therapies Show Delayed Mortality Benefit in ATTR-CM
Optimized Pacing Eases oHCM Symptoms in EMORI-HCM Trial
Written by: Radcliffe Cardiology
Optimized Pacing Eases oHCM Symptoms in EMORI-HCM Trial
Optimized Pacing Eases oHCM Symptoms in EMORI-HCM Trial
Written by: Radcliffe Cardiology
Optimized Pacing Eases oHCM Symptoms in EMORI-HCM Trial
Social Factors Impact Outcomes in HCM Patients
Written by: Radcliffe Cardiology
Social Factors Impact Outcomes in HCM Patients
Clinical Frailty Scale Predicts Mortality in Heart Failure
Written by: Radcliffe Cardiology
Clinical Frailty Scale Predicts Mortality in Heart Failure
ESPRIT: Intensive BP Control Benefits Frail Patients
Written by: Radcliffe Cardiology
ESPRIT: Intensive BP Control Benefits Frail Patients

External news

Written by: Academic - advance access - HF
Current state of knowledge on the epidemiology, aetiology, diagnosis, and management of heart involvement in eosinophilia. A Clinical Consensus Statement of the ESC Working Group on Myocardial & Pericardial Diseases
Written by: Academic - advance access - HF
The Rising Dominance of HFpEF: Addressing Epidemiological Disparities and the Imperative for Prevention
Written by: Academic - advance access - HF
Median Survival Among Patients Hospitalized for Heart Failure with Reduced Ejection Fraction Prescribed Quadruple Medical Therapy
Written by: Academic - open access - HF
Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial
Written by: Academic - advance access - HF
Intravenous IRON supplementation in Heart Failure with Preserved Ejection Fraction and iron deficiency (IRON-HFpEF): a comprehensive phase II multicentre placebo-controlled randomised clinical trial
Written by: Academic - advance access - HF
Reply to “Letter regarding the article ‘Modification of the association between age and mortality in heart failure by frailty status”
Written by: Academic - open access - HF
Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy
Written by: Academic - advance access - HF
Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy
Written by: Academic - advance access - HF
Letter regarding the article 'Modification of the association between age and mortality in heart failure by frailty status’
Written by: Academic - advance access - HF
Natriuretic Peptide Testing in Primary Care: The Evidence is Settled, Implementation is Not